#ASCO21: SQZ offers first clinical glimpse of unorthodox cell therapy manufacturing tech — but checkpoint combo is still the way to go

More than seven years after Armon Sharei, then a PhD student at Bob Langer’s lab, first published a way to reengineer …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AS­CO21: SQZ of­fers first clin­i­cal glimpse of un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech — but check­point com­bo is still the way to go